HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Abbott, MSD Pharmaceuticals enter into partnership
Jun-19-2025

Abbott and MSD Pharmaceuticals have entered into partnership for distribution of oral anti-diabetic medicines in India. Under a distribution agreement, Abbott will distribute the oral anti-diabetic medicine sitagliptin, its combination sitagliptin/metformin and the extended-release version of MSD Pharmaceuticals (MSD) in India. MSD's sitagliptin, its combination and extended-release versions are marketed under the brand names Januvia, Janumet and Janumet XR. Abbott will leverage its broad in-country footprint to continue to make these medicines available to people in India. 

Sitagliptin is a Dipeptidyl Peptidase IV Inhibitor (DPP4i) used for the treatment of Type 2 diabetes. It was discovered and developed by MSD Pharmaceuticals and was the first DPP4i to be launched in India in 2008.

Abbott India is one of the leading multinational pharmaceutical companies in India and operates with owned manufacturing units and various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily within India. 

  RELATED NEWS >>